2021
DOI: 10.1111/aos.14852
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Purpose: The primary endpoint results from the comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity (CARE-ROP) core study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP). This study reports the 1-and 2-year follow-up data focusing on long-term functional outcomes and safety. Methods:The CARE-ROP trial compared 0.12 mg versus 0.20 mg ranibizumab in 20 infants with ROP in a multicentric, prospective, randomized, double-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
10
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 18 publications
(11 citation statements)
references
References 33 publications
0
10
0
1
Order By: Relevance
“…12,25 It would be helpful to develop strategies for early identification of infants who have a high risk of ROP reactivation, particularly because late reactivations can occur months after treatment, and strict adherence to follow-up regimens can be difficult. [9][10][11]26,27 In this study, eyes with reactivated ROP had a larger change in VSS between baseline and 1 week after injection compared with eyes that did not have reactivated ROP in the subsequent study period (Figure 5). There are several potential explanations for this finding.…”
Section: Discussionmentioning
confidence: 56%
“…12,25 It would be helpful to develop strategies for early identification of infants who have a high risk of ROP reactivation, particularly because late reactivations can occur months after treatment, and strict adherence to follow-up regimens can be difficult. [9][10][11]26,27 In this study, eyes with reactivated ROP had a larger change in VSS between baseline and 1 week after injection compared with eyes that did not have reactivated ROP in the subsequent study period (Figure 5). There are several potential explanations for this finding.…”
Section: Discussionmentioning
confidence: 56%
“…A previous study also reported that follow-up in the first 12wk after IVR treatment was important for timely identification of ROP recurrences [19] . Several late recurrence cases (even 2.5y later) have shown the need for long-term examinations after anti-VEGF agent monotherapy for ROP [33][34][35] . Thus, after the initial IVR treatment, it is important to conduct follow-ups in the first 12wk for timely identification of ROP recurrences.…”
Section: Discussionmentioning
confidence: 99%
“…Regarding the effect of anti-VEGF on neurological development, some studies suggested that IVB could cause early neurodevelopmental disorders ( 24 , 25 ). While Stahl A et al followed sixteen ROP infants treated with IVR for two years and found no relationship between IVR and neurodevelopmental disabilities ( 26 ). Therefore, a better understanding of the role of anti-VEGF in neurodevelopmental disorders requires further analysis.…”
Section: Discussionmentioning
confidence: 99%